Featured Articles

  1. The Parameters That Matter In Cryopreservation And Cell Thawing Process Development 6/6/2019

    We are trying to simplify freezing and thawing protocols, basing them on biology and physics, and it is important to define these final steps to reduce wasting time, effort, and money. Delve into the science of cell thawing.

  2. GMP Cell Therapy Manufacturing: How And When To Get Started 5/2/2019

    As hospitals and translational facilities explore implementation, they concurrently evaluate whether or not to manufacture the therapies onsite. Here is a guideline of how and when to get started.

  3. Cell Therapy Manufacturing: The Supply Chain Challenge 4/1/2019

    Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Two industry experts detail strategies to meet supply chain challenges.

  4. Is A Rapid Cooling Step Needed When Freezing Cells For Cryopreservation? 3/6/2019

    A “rapid-cooling nucleation step” is hypothesized to improve ice nucleation – an important event for good post-thaw outcomes. Explore how a rapid-cooling nucleation step affects viable cell count and activity of four cell lines.

  5. De-Mystifying, De-Risking Process Development With A CDMO 11/27/2018

    An overview of how CDMOs can help companies get started in the world of CGT manufacturing, with considerations around timing of engagement to maximize commercial and clinical success.

  6. Factory-In-A-Box Scales Up Manufacturing Of Viral Vector Based Therapies 8/31/2018

    Manufacturing viral vector-based therapies such as vaccines and gene and cell therapies is complex, but a new manufacturing solution helps solve those challenges.

  7. Effective Separation Of Full And Empty AAV Capsids By Anion Exchange

    We show how Capto Q resin with dextran surface extenders, magnesium chloride (MgCl2), and the elution salt type (especially for rAAV9) significantly enhance separation.

  8. The Future Of Precision Medicine In China

    China is quickly becoming a world leader in biopharma, with rapid build-out of gene and cell therapy production capacity and a robust pipeline of drugs in development.